Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma

Background: NL101 has shown activities against multiple myeloma and acute myeloid leukemia, but its anti-lymphoma activity remains unknown. The transcription factor c-Myc is frequently dysregulated in aggressive B cell lymphomas such as double-hit lymphoma, for which the standard of care is still la...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shu, He, Xin, Gan, Yichao, Zhang, Jiawei, Gao, Feiqiong, Lin, Limin, Qiu, Xi, Yu, Teng, Zhang, Xuzhao, Chen, Panpan, Tong, Jiefeng, Qian, Wenbin, Xu, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847677/
https://www.ncbi.nlm.nih.gov/pubmed/33537096
http://dx.doi.org/10.7150/thno.53561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847677/
https://www.ncbi.nlm.nih.gov/pubmed/33537096
http://dx.doi.org/10.7150/thno.53561

Ejemplares similares